Role of randomized phase III trials in an era of effective targeted therapies (Q37964935)

26 August 2017

Role of randomized phase III trials in an era of effective targeted therapies (English)

1 reference

26 August 2017

phase III clinical trial

0 references

author name string

Manish R Sharma

series ordinal

1

1 reference

PubMed ID

22143142

26 August 2017

Richard L Schilsky

series ordinal

2

1 reference

PubMed ID

22143142

26 August 2017

language of work or name

English

0 references

publication date

6 December 2011

1 reference

Nature Reviews Clinical Oncology

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

4

1 reference

26 August 2017

208-214

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Accelerated approval of oncology products: the food and drug administration experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Randomized phase II trials: a long-term investment with promising returns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Progression-free survival is a surrogate for survival in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Availability of experimental therapy outside oncology randomized clinical trials in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Changing end points in breast-cancer drug approval--the Avastin story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Unmeasured costs of a child's death: perceived financial burden, work disruptions, and economic coping strategies used by American and Australian families who lost children to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Seamlessly expanding a randomized phase II trial to phase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Outcome--adaptive randomization: is it useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Equipoise and the Dilemma of Randomized Clinical Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Balancing Access and Evaluation in the Approval of New Cancer Drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Accrual to cancer clinical trials in the era of molecular medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Minimizing bias in randomized trials: the importance of blinding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

Adaptive clinical trials in oncology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2011.190

New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule

31 March 2020

1 reference

12 December 2020

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

1 reference

12 December 2020

Equipoise: asking the right questions for clinical trial design

1 reference

12 December 2020

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

1 reference

12 December 2020

10.1038/NRCLINONC.2011.190

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22143142